JNJ-26489112

CAS Number

• 871824-55-4 ^Y

PubChem CID

• 11616111

ChemSpider

• 9790860

UNII

• G1TI012DLT

JNJ-26489112

Identifiers
IUPAC name (S)-N-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
CAS Number	871824-55-4 Y
PubChem CID	11616111
ChemSpider	9790860
UNII	G1TI012DLT
CompTox Dashboard (EPA)	DTXSID601031470
Chemical and physical data
Formula	C9H11ClN2O4S
Molar mass	278.71 g·mol−1
3D model (JSmol)	Interactive image
SMILES NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
InChI InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1 Key:KXSAIQPPGSSNKX-ZETCQYMHSA-N

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy.^[1][2][3] JNJ-26489112 was designed as a successor to topiramate.^[4] It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.^[4]

JNJ-26489112 was studied as a treatment for major depressive disorder.^[5] This clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of JNJ-26489112 has been reported.

Its mechanism of action is unknown.^[6]